Clinical trials: Empagliflozin
Diabetes Mellitus, Type 2, Coronary Heart Disease
Effect of Empagliflozin on Ventricular Repolarization.
The present project aims to investigate if the empagliflozin has an antiarrhythmic action. Analyzing the T-wave heterogeneity index, a new electrocardiographic risk marker associated with the prediction of cardiovascular risk, in…
- Conditions
- Diabetes Mellitus, Type 2, Coronary Heart Disease, Arrythmia, Cardiac
- Trial name
- EMPATHYHEART (NCT04117763)
- Testing
- Empagliflozin 25 MG
- Where
- Brazil
- Volunteers
- 90 people
- Sponsor
- University of Sao Paulo
Diabetes Mellitus and Heart Failure
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
This was a dose-finding study to evaluate the efficacy, safety and tolerability of 3 different doses of LIK066 compared to placebo or empagliflozin in T2DM patients with heart failure
- Trial name
- NCT03152552
- Testing
- LIK066, Empagliflozin
- Where
- 106 sites in United States, Argentina and 22 more
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes
SGLT2i, Hepatic Glucose Production, and SNS
In this study, PI will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D)…
- Trial name
- NCT07053293
- Testing
- Empagliflozin 25 MG
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Heart Failure Due to Coronary Artery Disease, Valvular Cardiomyopathy
Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study
In patients with heart failure due to a reversible underlying cause-such as valvular heart disease or coronary artery disease-surgical or procedural correction of the underlying lesion (valve repair/replacement, TAVI, PCI, or…
- Conditions
- Heart Failure Due to Coronary Artery Disease, Valvular Cardiomyopathy, Heart Failure
- Trial name
- NCT07572032
- Testing
- Sacubitril / Valsartan, SGLT-2 inhibitor, SGLT2 Inhibition
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Kyungsub Song
Diabete Mellitus
Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients
Total of 360 participants were enrolled and prescribed oral 200 mg SGLT-2 tablet. All participants were followed-up for about three months.
- Trial name
- NCT07367555
- Testing
- Oral 100 gram Empagliflozin tablet along with diet plan and exercise, Diet plan and exercise
- Where
- Pakistan
- Volunteers
- 360 people
- Sponsor
- Ariba Shafiq
Hepatic Glucose Metabolism
Empagliflozin and Hepatic Glucose Metabolism
the aim of this study is to examine the role of autonomic nervous system in the increase in hepatic glucose production in response to glucosuria caused by inhibition of renal glucose uptake
- Trial name
- NCT03193684
- Testing
- Empagliflozin 25 MG, Control
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
This is a multi-center, randomised, double-blind, placebo-controlled, parallel-group, efficacy and safety study of empagliflozin as add-on to insulin in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic…
- Trial name
- NCT02589639
- Testing
- Empagliflozin
- Where
- 48 sites in Japan
- Volunteers
- 269 people
- Sponsor
- Boehringer Ingelheim
CAD - Coronary Artery Disease, Inflamation
Effect of Empagliflozin on Inflammation
Empagliflozin is a drug given to lower glucose. It is used in the treatment of diabetes. However, it was shown to improve symptoms and survival of patients who are suffering from heart failure.
- Conditions
- CAD - Coronary Artery Disease, Inflamation, PCI, SGLT 2 Inhibitors
- Trial name
- EMPANTINFLAM (NCT07292909)
- Testing
- Empagliflozin (SGLT2i)
- Where
- Lebanon
- Volunteers
- 100 people
- Sponsor
- Hotel Dieu de France Hospital
Severe Aortic Valve Stenosis
A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis
This study will include patients with severe degenerative aortic stenosis (AS) who meet the inclusion criteria and voluntarily participate (planned to undergo TAVI), as well as patients with aortic stenosis who have not undergone…
- Trial name
- NCT07335900
- Testing
- Transcatheter Aortic Valve Implantation, Optimal medication treatment
- Where
- China
- Volunteers
- 25 people
- Sponsor
- RenJi Hospital
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes
Antidiabetic Drugs for Steatotic Liver Disease
To investigate the synergic therapeutic effect of thiazolidinediones and SGLT2 inhibitor on metabolic dysfunction-associated steatotic liver disease, the effect of empagliflozin 10mg, pioglitazone 15mg monotherapy and combination…
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes, Digestive System Disease, Liver Diseases
- Trial name
- NCT03646292
- Testing
- Pioglitazone, Empagliflozin, Combination of pioglitazone and empagliflozin
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Yonsei University
Prediabetic State, Insulin Resistance
Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes
Type 2 diabetes is a worldwide epidemic disease, and preventive strategies are needed to face this health problem. The goal of this trial is to evaluate the effect of empagliflozin + linagliptin + metformin + lifestyle on…
- Trial name
- 4T (NCT04131582)
- Testing
- Linagliptin + metformin and Empagliflozin + metformin, Metformin
- Where
- Mexico
- Volunteers
- 34 people
- Sponsor
- Universidad de Guanajuato
Kidney Stone
Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers
The aim of this study is to test the effect of a new drug on the composition of the urine in kidney stone patients. This new drug (Jardiance®, substance: empagliflozin) is currently approved in Switzerland for the treatment of…
- Trial name
- SWEETSTONE (NCT04911660)
- Testing
- Empagliflozin 25 MG
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Maturity-Onset Diabetes of the Young, Type 3, Type 2 Diabetes
Impact of SGLT2 on Glucosuria in HNF1A-MODY
Maturity onset diabetes of the young (MODY) is a subtype of diabetes which is caused by mutations in specific genes leading to diabetes.
- Trial name
- MOD3ST-CLAMP (NCT05417646)
- Testing
- Hyperglycaemic clamp, Empagliflozin
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Steno Diabetes Center Copenhagen
Aortic Valve Stenosis
EMPagliflozin After Aortic Valve Replacement
The study is a randomized, placebo-controlled, and double-blinded trial in patients with aortic stenosis (AS) undergoing aortic valve replacement (AVR).
- Trial name
- EMPAVR (NCT06171802)
- Testing
- Empagliflozin
- Where
- Denmark
- Volunteers
- 206 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Heart Failure
The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission.
Heart failure (HF) is a chronic condition that is characterized by a weakened and enlarged heart. It typically causes symptoms such as breathlessness and swelling of the legs, and it is a serious illness that shortens life…
- Trial name
- TAPERED-HF (NCT07513883)
- Testing
- Down-titration, Continuation of guideline-directed heart failure therapy
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Ziekenhuis Oost-Limburg
Type 2 Diabetes Mellitus
Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin
This study is to evaluate pharmacokinetic drug interaction between teneligliptin and empagliflozin in healthy adults.
- Trial name
- NCT04431141
- Testing
- Teneligliptin, Empagliflozin, Teneligliptin and Empagliflozin
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Handok Inc.
Healthy
Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers
Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 10773 administered to healthy Japanese male subjects with single rising oral doses (1, 5, 10, 25, and 100 mg).
- Trial name
- NCT02182453
- Testing
- BI 10773 - single rising dose
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes
Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes
The goal of this 26-week multicenter, randomized, parallel, placebo-controlled trial is to test the effectiveness of empagliflozin use in conjunction with automated insulin delivery (AID) to improve glucose control in individuals…
- Trial name
- NCT06021145
- Testing
- Empagliflozin
- Where
- Canada
- Volunteers
- 46 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Diabetes Mellitus, Type 2
GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial
Three SGLT2i were commercially available in Italy at the time the trial was designed: canagliflozin, dapagliflozin, and empagliflozin.
- Trial name
- GOLDEN-AGE (NCT04796428)
- Testing
- Canagliflozin, Dapagliflozin, Empagliflozin
- Volunteers
- 1,167 people
- Sponsor
- Center for Outcomes Research and Clinical Epidemiology, Italy
Diabetes Mellitus, Type 2
A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes
Description of the real-life treatment of adult patients with type-2 diabetes mellitus (T2DM) receiving Empagliflozin, comparing the characteristics of patients starting Empagliflozin in three time intervals
- Trial name
- EDCOS (NCT04098575)
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 9,571 people
- Sponsor
- Boehringer Ingelheim